H.R. 2483 · 119th Congress · Health
SUPPORT for Patients and Communities Reauthorization Act of 2025
How the House voted
Yea from the left, nay from the right, each side by party
House · Jun 4, 2025
Roll call ↗366
57
Passed the House.
Law 245 days after it was introduced
Public Law 119-44. Each step dated from the congress.gov record
- IntroducedMar 31, 2025
- CommitteeMay 29, 2025
- Passed HouseJun 4, 2025
- Passed SenateSep 18, 2025
- Became lawDec 1, 2025
On the record
- Cosponsors
- 1
- all Democrat
- Committees
- Senate Committee on Health, Education, Labor, and PensionsHouse Committee on Financial ServicesHouse Committee on the JudiciaryHouse Committee on Education and WorkforceHouse Committee on Energy and Commerce
- Lobbying
- At least 52
- organizations named it2025 Q1 to 2026 Q3
What it does
The law reauthorizes and updates a wide set of substance use disorder programs, extending funding through fiscal years 2026 to 2030.
How each member voted
The House roll call, passed the House, June 4, 2025
Yea unless marked
D · House · NC-12
R · House · AL-4
D · House · CA-33
R · House · MO-4
R · House · GA-12
The law reauthorizes and updates a wide set of substance use disorder programs, extending funding through fiscal years 2026 to 2030. It is organized into prevention, treatment, and recovery titles plus miscellaneous matters. On prevention, it sets new funding levels for programs including preventing overdoses of controlled substances at $505,579,000 per year for fiscal years 2026 to 2030, first responder training at $57,000,000 per year, and a rewritten fetal alcohol spectrum disorder program at $12,500,000 per year. It adds cybersecurity reporting duties for the 988 Suicide and Crisis Lifeline and orders a GAO study of the Lifeline's cybersecurity risks. It broadens overdose prevention grants to allow fentanyl and xylazine test strips where legal, and directs HHS to publish guidance on at-home drug disposal systems and a plan for assessing approved opioid analgesic drugs. On treatment, it raises authorized funding for residential treatment for pregnant and postpartum women and for the substance use disorder treatment workforce loan repayment program, and directs HHS to review the scheduling of buprenorphine-naloxone products. On recovery, it reauthorizes building communities of recovery, comprehensive opioid recovery centers, youth prevention and recovery, and the CAREER Act workforce grants, and reauthorizes the recovery housing pilot program through 2030. In miscellaneous matters, it expands when a pharmacy may deliver a schedule III, IV, or V controlled substance to a prescribing practitioner for maintenance or detoxification treatment or for a drug under a risk evaluation and mitigation strategy, and it adds professional organizations to the list qualifying for the controlled substance prescriber training requirement, effective as if enacted December 29, 2022.
Each stop is a step the bill’s own record states, with the date it happened. A ring is a step not yet taken. A bill becomes law when the President signs it or Congress overrides a veto.
At least 52 organizations named this measure in a lobbying filing. A floor, not a total: they were counted by the client name on 224 quarterly reports filed by 17 lobbying firms and by 33 organizations lobbying for themselves in 2025 Q1, 2025 Q2, 2025 Q3, 2025 Q4, 2026 Q1, 2026 Q2 and 2026 Q3. An organization that lobbied this measure without naming it is not counted here.
The filings record that lobbying was reported on the measure. The form has no per-bill dollar figure and no field for a position, so nothing here says how much was spent or which side an organization took.
5 of them, in no ranking: National Council for Behavioral Health; The American Occupational Therapy Association, Inc. (AOTA); Healthcare Leadership Council; National Association of Boards of Pharmacy; Massachusetts Medical Society. Listed as filed, in the order the filings were read, and 47 others are not shown. These are not the largest, the earliest or the most active: we keep five names per measure, and the filings give no ranking.
From the LD-2 quarterly lobbying filings published at lda.gov by the Senate Office of Public Records. Read for 2025 Q1, 2025 Q2, 2025 Q3, 2025 Q4, 2026 Q1, 2026 Q2 and 2026 Q3. Our copy holds 24 fewer filings for 2025 Q1, 39 fewer filings for 2025 Q2, 42 fewer filings for 2025 Q3, 33 fewer filings for 2025 Q4, 28 fewer filings for 2026 Q1, 48 fewer filings for 2026 Q2 and 218 fewer filings for 2026 Q3 than the Senate's register counts, so those quarters are the filings we could read rather than every one filed. 2026 Q4 is still inside its filing window, so that quarter is only the filings posted so far.
Congress.gov bill status and cosponsor records; the House Clerk and Senate roll calls; lobbying reports filed under the Lobbying Disclosure Act (lda.gov); the plain summary and provisions are read from the bill text, each with its section.